>GFP

atggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgcgcggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggcttcgtccaggagcgcaccatcagcttcaaggacgacggcaactacaagacccgcgccgtggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcaccgacttcaaggaggacggcaacatcctggggcacaagctggagtacaacttcaacagccacaacgtctatatcaccgccgacaagcagaagaacggcatcaaggccaacttcaccgtgcgccacaacgtggaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagacggtgctgagcaaagaccccaacgagaagcgcgatcacatggtcctgcacgagtacgtgaacgccgccgggatcactctcggcatggacgagctgtacaagtag

**Additional File 3 (.docx).** Sequence of GFP used in this study. This is a version of eGFP which contains solubility-enhancing point mutations (Cabantous et al., 2005; Pedelacq et al., 2006).